Inventor

COLLINS PETER L

US53 patents

⚠️ This page may combine multiple inventors who share the name “COLLINS PETER L”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

COLLINS PETER L

US HEALTH

Methods for producing self-replicating infectious RSV particles comprising recombinant RSV genomes or antigenomes and the N, P, L, and M2 proteins

Product of infectious respiratory syncytial virus from cloned nucleotide sequences

Attenuated chimeric respiratory syncytial virus

Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences

Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences

Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein

Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences

Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene

Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens

Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2

Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences

Attenuated parainfluenza virus (PIV) vaccines

Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines

Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)

Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes

Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines

Production of novel Newcastle disease virus strains from cDNAs and improved live attenuated Newcastle disease vaccines

Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines

Recombinant human metapneumovirus and its use

Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization

Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes

Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2

Genetically stable live attenuated respiratory syncytial virus vaccine and its production

Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines

Production of attenuated, human-bovine chimeric respiratory syncytial viruses for use in immunogenic compositions

Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes

Polynucleotides encoding recombinant respiratory syncytial viruses expressing immune modulatory molecules

Recombinant chimeric bovine/human parainfluenza virus 3 expressing rsv g and its use

Genetically stable live attenuated respiratory syncytial virus vaccine and its production

Chimeric vectors

Recombinant respiratory syncytial virus strains with mutations in the M2-2 ORF providing a range of attenuation phenotypes

Recombinant respiratory syncytial virus strains comprising NS1 and NS2 gene shifts

Recombinant respiratory syncytial virus strains comprising NS1 and NS2 gene shifts

Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens

Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines

Negative strand RNA virus replicon

Genetically stable live attenuated respiratory syncytial virus vaccine and its production

THE USA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES

Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes

Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization

Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes

Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes

THE US SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

Recombinant chimeric bovine/human parainfluenza virus 3 expressing RSV G and its use

Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization

UNIV NORTH CAROLINA

Vaccines for human respiratory virus

(unassigned)

Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules

USA

Recovery of recombinant human parainfluenza virus type 1 (HPIV1) from cDNA and use of recombinant HPIV1 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens

SAMAL SIBA K

Genomic sequence of avian paramyxovirus type 2 and uses thereof

US SEC THE DEPT OF HEALTH & HUMAN SERVICES

Recovery of recombinant human parainfluenza virus type 2 (HYPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens

UPJOHN CO

Human respiratory virus preparahons and processess

THE USA AS REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES

Method of vaccination with an attenuated RSV vaccine formulation